British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...

Quarterly Net Profit at Rs. 262.87 crore in March 2025 up 35.17% from Rs. 194.48 crore in March 2024. EBITDA stands at Rs. 373.87 crore in March 2025 up 30.23% from Rs. 287.09 crore in March 2024.

Witty will act as a senior advisor to his successor, Stephen Hemsley, who served as UnitedHealth Group’s CEO from 2006 to ...

GlaxoSmithKline Pharmaceuticals reported a 36% rise in consolidated net profit to Rs 263 crore in the March quarter, driven by strong growth in its diversified portfolio. Revenue also increased to Rs ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.00. Protect Your Portfolio Against Market Uncertai ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

GlaxoSmithKline Pharmaceuticals on Tuesday said its consolidated net profit increased 36 per cent to Rs 263 crore during the March quarter. The company rep ...